112334-46-0Relevant academic research and scientific papers
Pyridone-conjugated monobactam antibiotics with gram-negative activity
Brown, Matthew F.,Mitton-Fry, Mark J.,Arcari, Joel T.,Barham, Rose,Casavant, Jeffrey,Gerstenberger, Brian S.,Han, Seungil,Hardink, Joel R.,Harris, Thomas M.,Hoang, Thuy,Huband, Michael D.,Lall, Manjinder S.,Lemmon, M. Megan,Li, Chao,Lin, Jian,McCurdy, Sandra P.,McElroy, Eric,McPherson, Craig,Marr, Eric S.,Mueller, John P.,Mullins, Lisa,Nikitenko, Antonia A.,Noe, Mark C.,Penzien, Joseph,Plummer, Mark S.,Schuff, Brandon P.,Shanmugasundaram, Veerabahu,Starr, Jeremy T.,Sun, Jianmin,Tomaras, Andrew,Young, Jennifer A.,Zaniewski, Richard P.
supporting information, p. 5541 - 5552 (2013/07/26)
Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.
MONOBACTAMS
-
Page/Page column 54, (2012/06/16)
The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.
MONOCARBAMS
-
Page/Page column 19-20, (2010/07/04)
The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, Rs, and R6 as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of formula (I)
3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
-
, (2008/06/13)
Compounds having the formula and pharmaceutically acceptable salts thereof, exhibit antibacterial activity.
1-(substituted phosphorous)-azetidinone antibacterials
-
, (2008/06/13)
Antibacterial activity is exhibited by 2-azetidinones having an acylamino substituent in the 3-position and having an activating group in the 1-position of the formula STR1
2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
-
, (2008/06/13)
Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula STR1
2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
-
, (2008/06/13)
Antibacterial activity is exhibited by 3-acylamino-2-oxoazetidines having in the 1-position an activating group of the formula STR1 wherein R is STR2 and R4 is STR3
